-
Something wrong with this record ?
The Czech National MS Registry (ReMuS): Data trends in multiple sclerosis patients whose first disease-modifying therapies were initiated from 2013 to 2021
D. Stastna, J. Drahota, M. Lauer, A. Mazouchova, I. Menkyova, J. Adamkova, R. Ampapa, M. Dufek, M. Grunermelova, P. Hradilek, E. Kubala Havrdova, J. Mares, A. Martinkova, Z. Pavelek, M. Peterka, E. Recmanova, P. Rockova, I. Stetkarova, P....
Language English Country Czech Republic
Document type Journal Article
NLK
Directory of Open Access Journals
from 2001
Free Medical Journals
from 1998
Medline Complete (EBSCOhost)
from 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
from 2001
PubMed
37114703
DOI
10.5507/bp.2023.015
Knihovny.cz E-resources
- MeSH
- Adult MeSH
- Immunologic Factors therapeutic use MeSH
- Immunosuppressive Agents therapeutic use MeSH
- Humans MeSH
- Registries * MeSH
- Multiple Sclerosis * drug therapy MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic MeSH
AIMS: Multiple sclerosis treatment strategies are changing in the Czech Republic. According to data from 2013-2021, the proportion of patients starting high-efficacy disease-modifying therapies is increasing. In this survey, we describe the actual data trends in multiple sclerosis (MS) patients beginning their first disease‐modifying therapies (DMTs) from 2013 to 2021. The secondary objective was to present the history, data collection, and scientific potential of the Czech National MS registry (ReMuS). METHODS: First, using descriptive statistics, we analysed the data for patients starting their first DMTs, either platform (including dimethyl fumarate) or high-efficacy DMTs (HE-DMTs), for each successive year. Second, a detailed description of the history, data collection, completeness, quality optimising procedures, and legal policies of ReMuS is provided. RESULTS: Based on the dataset from December 31, 2021, the total number of monitored patients with MS in ReMuS increased from 9,019 in 2013 (referred from 7 of 15 MS centres) to 12,940 in 2016 (referred from all 15 Czech MS centres) to 17,478 in 2021. In these years, the percentage of patients treated with DMTs in the registry ranged from 76 to 83%, but the proportion of patients treated with HE-DMTs changed from 16.2% in 2013 to 37.1% in 2021. During the follow-up period, a total of 8,491 treatment-naive patients received DMTs. The proportion of patients (all MS phenotypes) starting HE-DMTs increased from 2.1% in 2013 to 18.5% in 2021. CONCLUSION: Patient registries, including ReMuS, provide an essential quality data source, especially in light of the increasing percentage of patients on HE-DMTs. Although early initiation of HE-DMT can provide considerable benefits, it also carries greater potential risks. Consistent long-term follow-up of patients in real‐world clinical practice, which only registries allow, is therefore crucial to evaluate the efficacy and safety of therapeutic strategies, for epidemiological research and to assist decision making by healthcare providers and regulatory bodies.
1st Department of Neurology Masaryk University St Anne's University Hospital Brno Czech Republic
2nd Department of Neurology Faculty of Medicine Comenius University Bratislava Slovak Republic
Department of Economic Statistics Prague University of Economics and Business Prague Czech Republic
Department of Neurology Hospital Ceske Budejovice Ceske Budejovice Czech Republic
Department of Neurology Hospital of Jihlava Jihlava Czech Republic
Department of Neurology KZ a s Hospital Teplice Teplice Czech Republic
Department of Neurology Thomayer Hospital Prague Czech Republic
Department of Neurology Tomas Bata Regional Hospital Zlin Czech Republic
Department of Neurology University Hospital Ostrava Ostrava Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24017561
- 003
- CZ-PrNML
- 005
- 20250507135843.0
- 007
- ta
- 008
- 241004s2024 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2023.015 $2 doi
- 035 __
- $a (PubMed)37114703
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Šťastná, Dominika $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic $7 xx0264599
- 245 14
- $a The Czech National MS Registry (ReMuS): Data trends in multiple sclerosis patients whose first disease-modifying therapies were initiated from 2013 to 2021 / $c D. Stastna, J. Drahota, M. Lauer, A. Mazouchova, I. Menkyova, J. Adamkova, R. Ampapa, M. Dufek, M. Grunermelova, P. Hradilek, E. Kubala Havrdova, J. Mares, A. Martinkova, Z. Pavelek, M. Peterka, E. Recmanova, P. Rockova, I. Stetkarova, P. Stourac, M. Vachova, D. Horakova
- 520 9_
- $a AIMS: Multiple sclerosis treatment strategies are changing in the Czech Republic. According to data from 2013-2021, the proportion of patients starting high-efficacy disease-modifying therapies is increasing. In this survey, we describe the actual data trends in multiple sclerosis (MS) patients beginning their first disease‐modifying therapies (DMTs) from 2013 to 2021. The secondary objective was to present the history, data collection, and scientific potential of the Czech National MS registry (ReMuS). METHODS: First, using descriptive statistics, we analysed the data for patients starting their first DMTs, either platform (including dimethyl fumarate) or high-efficacy DMTs (HE-DMTs), for each successive year. Second, a detailed description of the history, data collection, completeness, quality optimising procedures, and legal policies of ReMuS is provided. RESULTS: Based on the dataset from December 31, 2021, the total number of monitored patients with MS in ReMuS increased from 9,019 in 2013 (referred from 7 of 15 MS centres) to 12,940 in 2016 (referred from all 15 Czech MS centres) to 17,478 in 2021. In these years, the percentage of patients treated with DMTs in the registry ranged from 76 to 83%, but the proportion of patients treated with HE-DMTs changed from 16.2% in 2013 to 37.1% in 2021. During the follow-up period, a total of 8,491 treatment-naive patients received DMTs. The proportion of patients (all MS phenotypes) starting HE-DMTs increased from 2.1% in 2013 to 18.5% in 2021. CONCLUSION: Patient registries, including ReMuS, provide an essential quality data source, especially in light of the increasing percentage of patients on HE-DMTs. Although early initiation of HE-DMT can provide considerable benefits, it also carries greater potential risks. Consistent long-term follow-up of patients in real‐world clinical practice, which only registries allow, is therefore crucial to evaluate the efficacy and safety of therapeutic strategies, for epidemiological research and to assist decision making by healthcare providers and regulatory bodies.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a registrace $7 D012042
- 650 12
- $a roztroušená skleróza $x farmakoterapie $7 D009103
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a imunosupresiva $x terapeutické užití $7 D007166
- 650 _2
- $a imunologické faktory $x terapeutické užití $7 D007155
- 651 _2
- $a Česká republika $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Drahota, Jiří $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic $u Endowment Fund IMPULS, Prague, Czech Republic $7 xx0269357
- 700 1_
- $a Lauer, Michal $u Endowment Fund IMPULS, Prague, Czech Republic $u Department of Economic Statistics, Prague University of Economics and Business, Prague, Czech Republic $7 _AN122460
- 700 1_
- $a Mazouchová, Aneta $u Endowment Fund IMPULS, Prague, Czech Republic $u Department of Economic Statistics, Prague University of Economics and Business, Prague, Czech Republic $7 xx0269359
- 700 1_
- $a Menkyová, Ingrid $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic $u 2nd Department of Neurology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic $7 xx0255824
- 700 1_
- $a Adámková, Jana $u Department of Neurology, Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic $7 xx0239455
- 700 1_
- $a Ampapa, Radek $u Department of Neurology, Hospital of Jihlava, Jihlava, Czech Republic $7 mzk2018987225
- 700 1_
- $a Dufek, Michal $u First Department of Neurology, Masaryk University, St. Anne's University Hospital, Brno, Czech Republic $7 xx0098436
- 700 1_
- $a Grünermelová, Markéta $u Department of Neurology, Thomayer Hospital, Prague, Czech Republic $7 xx0096028
- 700 1_
- $a Hradílek, Pavel $u Department of Neurology, University Hospital Ostrava, Ostrava, Czech Republic $7 xx0076908
- 700 1_
- $a Kubala Havrdová, Eva, $d 1955- $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic $7 nlk19990073204
- 700 1_
- $a Mareš, Jan $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic $7 xx0060341
- 700 1_
- $a Martínková, Alena $u Department of Neurology, Hospitals of the Pardubice Region, Hospital of Pardubice, Pardubice, Czech Republic $7 _AN119454
- 700 1_
- $a Pavelek, Zbyšek $u Department of Neurology, Charles University in Prague, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic $7 xx0139900
- 700 1_
- $a Peterka, Marek $u Department of Neurology, Charles University in Prague, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic $u Department of Neurology, Charles University in Prague, Faculty of Medicine in Pilsen and University Hospital Pilsen, Pilsen, Czech Republic $7 xx0225234
- 700 1_
- $a Recmanová, Eva $u Department of Neurology, Tomas Bata Regional Hospital, Zlin, Czech Republic $7 xx0256465
- 700 1_
- $a Ročková, Petra $u Department of Neurology, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic $7 xx0241089
- 700 1_
- $a Štětkářová, Ivana, $d 1963- $u Charles University in Prague, Third Faculty of Medicine, Charles University and Hospital Kralovske Vinohrady, Prague, Czech Republic $7 xx0030376
- 700 1_
- $a Štourač, Pavel, $d 1959- $u Department of Neurology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 xx0060352
- 700 1_
- $a Vachová, Marta $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic $u Department of Neurology, KZ a.s., Hospital Teplice, Teplice, Czech Republic $7 xx0100083
- 700 1_
- $a Horakova, Dana $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 168, č. 3 (2024), s. 262-270
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37114703 $y Pubmed
- 910 __
- $a ABA008 $b A 1502 $c 958 $y p $z 0
- 990 __
- $a 20241004 $b ABA008
- 991 __
- $a 20250507135840 $b ABA008
- 999 __
- $a ok $b bmc $g 2316481 $s 1229511
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 168 $c 3 $d 262-270 $e 20230428 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $n Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub $x MED00012606
- LZP __
- $b NLK124 $a Pubmed-20241004
